- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
Authors
Keywords
Immunotherapy, Ipilimumab, Nivolumab, Pembrolizumab, CD8, Prostate cancer, Cancer vaccine, Sipuleucel-T, GVAX, PROSTVAC-VF, ADX031-142, PD-1, PD-L1, CTLA-4, B7-H3, CAR T, Checkpoint inhibitors, Antibody-drug conjugates, PSMA ADC, J591, Bi-specific antibodies
Journal
Current Oncology Reports
Volume 20, Issue 9, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-18
DOI
10.1007/s11912-018-0712-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blocking PD-1/PD-L1 in Genitourinary Malignancies
- (2018) Matthew C. Dallos et al. CANCER JOURNAL
- Inhibitors of the PD-1 Pathway in Tumor Therapy
- (2018) Martin W. LaFleur et al. JOURNAL OF IMMUNOLOGY
- Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
- (2017) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment
- (2017) Yuki Muroyama et al. Cancer Immunology Research
- Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
- (2017) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- European cancer mortality predictions for the year 2016 with focus on leukaemias
- (2016) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
- (2016) Emmanuel S. Antonarakis et al. CLINICAL CANCER RESEARCH
- Valproate in Adjuvant Glioblastoma Treatment
- (2016) Michael F. Fay et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
- (2015) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Bispecific T-cell engagers for cancer immunotherapy
- (2014) Amelia M Huehls et al. IMMUNOLOGY AND CELL BIOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
- (2014) Colin C. Pritchard et al. Nature Communications
- Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
- (2014) Harm Westdorp et al. Frontiers in Immunology
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer
- (2012) Raquibul Hannan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Development of Listeria monocytogenes–Based Immunotherapies
- (2012) Dung T. Le et al. SEMINARS IN ONCOLOGY
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Impact of tumour volume on the potential efficacy of therapeutic vaccines
- (2011) J. L. Gulley et al. Current Oncology
- Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
- (2011) Hitoe Torisu-Itakura et al. JOURNAL OF IMMUNOTHERAPY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Development of a Listeria monocytogenes based vaccine against prostate cancer
- (2008) Vafa Shahabi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now